This bill amends Alaska's insurance laws to require health care insurers to provide coverage for the prophylaxis, diagnosis, and treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome. The coverage must include a range of treatments such as antimicrobials, medication, behavioral therapies, immunomodulating medicines, plasma exchange, and intravenous immunoglobulin therapy. Insurers are prohibited from denying or delaying coverage based on previous treatments, diagnostic names, or age, and they cannot impose restrictions that are inconsistent with established treatment guidelines. Additionally, the bill ensures that coverage for these disorders is not more restrictive than coverage for other illnesses.

Furthermore, the bill expands the optional services under Alaska's medical assistance program to include treatment for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome. The Department of Health is tasked with amending the state plan for medical assistance coverage to align with these changes, which will take effect only upon approval from the U.S. Department of Health and Human Services. If approved, the new provisions will be implemented immediately; otherwise, the bill will take effect on January 1, 2027.

Statutes affected:
HB0292A, AM HB 292, introduced 02/04/2026:
HB0292B, AM CSHB 292(HSS), introduced 03/18/2026: 47.07.030, 47.07.063, 21.42.375, 21.42.450